News

Adult children of parents with chronic obstructive pulmonary disease (COPD) are at higher risk of developing the condition themselves, even when no apparent genetic risk factors for COPD are present. This insight indicates a need for better screening for COPD in this group of people to create a greater likelihood…

Researchers have engineered a mouse model of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD), with excessive mucus production, inflammation, and reduced lung function. Their hope is that the model will help with developing new treatments. The study explaining the development, “Pharmacological and genetic reappraisals of…

The Aerobika device, which Monaghan Medical Corporation (MMC) developed to ease symptoms of chronic obstructive pulmonary disease (COPD), may also be effective in patients with non-cystic fibrosis (CF) bronchiectasis, according to a study. The research, “Non-Cystic Fibrosis Bronchiectasis: Regional Abnormalities And Response To Airway Clearance Therapy Using Pulmonary Functional…

Speakers at the 13th Annual Asthma & COPD Conference on March 29-30 in London, England will discuss the latest developments in asthma and chronic obstructive pulmonary disease (COPD). This year’s event will gather industry leaders, scientists, and members of the community to debate and talk about the latest challenges in asthma and COPD. The…

People with chronic obstructive pulmonary disease (COPD) often have other chronic conditions, like heart disease, and those who are poor about keeping  up with treatments for these comorbidites are also less likely to adhere to their COPD medications, according to results of a U.S. study conducted by Boehringer Ingelheim and Humana. The study,  “…

Early detectionof bronchiectasis among patients with chronic obstructive pulmonary disease (COPD) could lead to better disease management and, in the long run, better survival. But researchers do not agree on the best way to manage these patients, emphasizing the need for more research in patients with the two conditions. Researchers…

Sunovion Pharmaceuticals and Novartis have entered a commercialization agreement for three drugs approved by the U.S. Food and Drug Administration (FDA) indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Utibron Neohaler (indacaterol and glycopyrrolate) inhalation powder (27.5 mcg/15.6…

A sugar molecule called keratan sulfate could play a protective role against inflammation and emphysema associated with chronic obstructive pulmonary disease (COPD), according to a new study. The study, “A Keratan Sulfate Disaccharide Prevents Inflammation And The Progression Of Emphysema In Murine Models,” was published in the American…

The National Heart, Lung and Blood Institute (NHLBI) has named the recipient of its inaugural Outstanding Investigator Award: Yvonne Janssen-Heininger, PhD, professor of pathology and laboratory medicine at the Larner College of Medicine at the University of Vermont, to conduct studies on antioxidant therapies for lung diseases, including chronic obstructive pulmonary…

A protein called Wnt5a seems to be involved in the development of chronic obstructive pulmonary disease (COPD), according to a study published recently in the Journal of Experimental Medicine. This finding may be a path to the development of new therapies targeting this protein. The study was published under…